Macrogenics (MGNX) Assets Average (2013 - 2026)
Macrogenics (MGNX) posted quarterly Assets Average of $237.4 million for Q1 2026, down 2.37% year-over-year from $243.1 million in Q1 2025, and down 10.02% quarter-over-quarter from $263.8 million in Q4 2025.
Analysis
Macrogenics (MGNX) Assets Average (2013 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Assets Average for 14 consecutive years, with $237.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 2.37% year-over-year to $237.4 million; the TTM figure through Mar 2026 stood at $237.4 million (down 2.37% YoY), while the FY2025 annual figure was $259.3 million, down 7.42% from the prior year.
- Assets Average retreated to $237.4 million in Q1 2026 per MGNX's latest filing, from $263.8 million in the prior quarter.
- Across five years, Assets Average topped out at $324.6 million in Q2 2023 and bottomed at $206.7 million in Q3 2022.
- Historically, Assets Average has averaged $264.9 million across 5 years, with a median of $258.1 million in 2025.
- Annual changes were most pronounced in 2022 — Assets Average slumped 49.47% — and 2023, when it soared 56.18%.
- Macrogenics' Assets Average stood at $237.9 million in 2022, then soared by 34.17% to $319.2 million in 2023, then decreased by 17.58% to $263.1 million in 2024, then advanced by 0.28% to $263.8 million in 2025, then slipped by 10.02% to $237.4 million in 2026.
- Business Quant data shows MGNX's Assets Average at $237.4 million in Q1 2026, $263.8 million in Q4 2025, and $258.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | 281.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 281.64 Mn |
| Mar 31, 2026 | 237.36 Mn |
| Dec 31, 2025 | 263.80 Mn |
| Sep 30, 2025 | 258.09 Mn |
| Jun 30, 2025 | 234.99 Mn |
| Mar 31, 2025 | 243.11 Mn |
| Dec 31, 2024 | 263.07 Mn |
| Sep 30, 2024 | 232.81 Mn |
| Jun 30, 2024 | 224.71 Mn |
| Mar 31, 2024 | 273.35 Mn |
| Dec 31, 2023 | 319.20 Mn |
| Sep 30, 2023 | 322.81 Mn |
| Jun 30, 2023 | 324.58 Mn |
| Mar 31, 2023 | 311.98 Mn |
| Dec 31, 2022 | 237.91 Mn |
| Sep 30, 2022 | 206.70 Mn |
| Jun 30, 2022 | 244.74 Mn |
| Mar 31, 2022 | 303.35 Mn |
| Dec 31, 2021 | 363.70 Mn |
| Sep 30, 2021 | 409.04 Mn |